Sign inJoin waitlistJoin the waitlist

Jun Gong

Current Scholar · Cedars-Sinai Medical Center

Credentials: · · · · · ·

History

Cedars-Sinai Medical Center
Present

Hematology and Medical Oncology
University of Southern California/Los Angeles General Medical Center
2015–2018
Internal Medicine
Cedars-Sinai Medical Center
2012–2015
Pediatrics
City of Hope Comprehensive Cancer Center
2012–2015
New York Medical College
2008–2012

Research

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Review · Journal for ImmunoTherapy of Cancer · 2018 · First of 4 authors · 1,025 citations
Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation
Case report · Journal of the National Comprehensive Cancer Network · 2017 · First of 5 authors · 178 citations
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Review · Journal for ImmunoTherapy of Cancer · 2018 · First of 5 authors · 170 citations

Andrew Hendifar
76 papers
Arsen Osipov
35 papers
May Cho
28 papers · 9 as a fellow
Alexandra Gangi
27 papers · 14 as a fellow
Katelyn Atkins
18 papers · 15 as a resident
Nicholas Nissen
18 papers
MF
Marwan Fakih
16 papers
Stephen Freedland
16 papers
Edwin Posadas
15 papers
Kevin Waters
15 papers · 4 as a fellow
Stephen Pandol
15 papers
Michelle Guan
13 papers

Grants

Universal Methylated ctDNA Markers for Minimal Residual Disease Detection and Therapy Response Prediction in Colorectal Cancer
National Cancer Institute · R37
Contact PI · $662.6K · Cedars-Sinai Medical Center
2026–2031
A Phase I Trial of S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas
National Cancer Institute · R21
Contact PI · $340.3K · Cedars-Sinai Medical Center
2026–2028

Clinical trials

S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas
Principal investigator · Not yet recruiting · Phase 1
Jun Gong, MD
2026–2028
Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
Principal investigator · Completed · Phase 1
Jun Gong, MD
2021–2025
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2027
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2023–2032